— Investors May Download New “SYN IR” iPhone App at Apple’s App Store —
ANN ARBOR, Mich., April 26, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today the release of its investor relations mobile iPhone App, called the “SYN IR” App, now available for free at the Apple App Store on the iPhone or iPad or at http://bit.ly/I9xDpW.
The Synthetic Biologics’ investor relations mobile iPhone App allows users to navigate the Company’s investor relations materials as well as receive a stock quote and other important stock information. Features in the “SYN IR” App include the latest press releases and SEC filings as well as a corporate fact sheet and listing of events.
“The launch of our investor relations iPhone App provides our current and potential shareholders with immediate access to financial and corporate information regarding the Company,” stated C. Evan Ballantyne, Chief Financial Officer at Synthetic Biologics. “With investors always on the move and spanning the globe, we recognize the growing importance of mobile technology. This new application allows our shareholders to have instant access to our corporate and stock information. We are excited to be one of the early adopters of mobile technology that is intended to help drive shareholder value and create broader awareness throughout the investment community.”
About Synthetic Biologics, Inc.
Synthetic Biologics is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. Synthetic Biologics is developing, or has partnered the development of, product candidates for the treatment of pulmonary arterial hypertension (PAH), relapsing-remitting multiple sclerosis (MS), cognitive dysfunction in MS, fibromyalgia and amyotrophic lateral sclerosis (ALS). For more information, please visit Synthetic Biologics’ website at www.syntheticbiologics.com.
This release includes forward-looking statements on Synthetic Biologics’ current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding driving shareholder value. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics’ forward-looking statements include, among others, a failure of the “SYN IR” App to provide its anticipated benefits and other factors described in Synthetic Biologics’ report on Form 10-K for the year ended December 31, 2011 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
SOURCE Synthetic Biologics, Inc.
Released April 26, 2012